StockWatch
·
Biotechnology: Pharmaceutical Preparations
Corporate ActionNov 17, 2026, 04:54 PM

Enlivex Ltd. Raises $0.5M in Direct Offering, Plans $7.0M More

AI Summary

Enlivex Ltd. announced a registered direct offering of ordinary shares and warrants, raising approximately $0.5 million in its initial closing on November 17, 2026. The company plans to issue additional shares and warrants over 10 monthly closings, potentially raising up to $7.0 million more, for a total of $7.5 million before expenses. The net proceeds will be used for clinical, regulatory, manufacturing, research and development activities, potential acquisitions, and general corporate purposes. The offering was made without a placement agent, and no fees are payable.

Key Highlights

  • Enlivex Ltd. completed an initial closing of a registered direct offering, raising approximately $0.5 million.
  • The company plans to raise an additional $7.0 million through 10 monthly closings, totaling $7.5 million.
  • Proceeds will fund clinical, regulatory, manufacturing, R&D, potential acquisitions, and general corporate purposes.
  • Ordinary Warrants have an exercise price of $1.578 and expire three years after the initial closing.
  • Pre-Funded Warrants have an exercise price of $0.001 and no expiration date.
  • Warrants are subject to a 19.99% beneficial ownership limitation upon exercise.